SGLT2 Inhibitors Underprescribed for Chronic Kidney Disease
Although clinical trials have demonstrated favorable cardiovascular and kidney effects from use of sodium-glucose cotransporter 2 (SGLT2) inhibitors, clinicians appear to be underprescribing these drugs to patients with chronic kidney disease (CKD), a real-world study…